Patents Assigned to Murdoch Childrens Research Institute
-
Patent number: 11819546Abstract: The present invention relates to method of treating and/or preventing inflammation in a subject caused by bacteria that express HtrA. The present invention further relates to immunogenic compositions comprising an HtrA polypeptide or fragment thereof, as well as a therapeutic and/or prophylactic vaccine for treating or preventing disease.Type: GrantFiled: August 27, 2021Date of Patent: November 21, 2023Assignee: Murdoch Childrens Research InstituteInventor: Philip Sutton
-
Publication number: 20230277606Abstract: The invention relates to allergic disease, to the development of allergic disease in infants, to determining the likelihood of development of allergic disease in infants and to minimizing the likelihood of development of allergic disease in infants.Type: ApplicationFiled: November 15, 2022Publication date: September 7, 2023Applicant: MURDOCH CHILDREN'S RESEARCH INSTITUTEInventors: Peter VUILLERMIN, Anne-Louise PONSONBY, Mimi TANG
-
Patent number: 11529380Abstract: The invention relates to allergic disease, to the development of allergic disease in infants, to determining the likelihood of development of allergic disease in infants and to minimizing the likelihood of development of allergic disease in infants.Type: GrantFiled: December 22, 2017Date of Patent: December 20, 2022Assignee: MURDOCH CHILDREN'S RESEARCH INSTITUTE ParkvilleInventors: Peter Vuillermin, Anne-Louise Ponsonby, Mimi Tang
-
Patent number: 11492644Abstract: Expression of exogenous SNAI2, EYA1 and SIX1 genes in a cell, tissue or organ not normally having nephron progenitor activity, induces or re-programs that cell to have or subsequently develop nephron progenitor activity. Nephron progenitors induced 5 by expression of SNAI2, EYA1 and SIX1 may be used for the production of nephron cells and tissues that are useful in treatment of kidney disorders, kidney regeneration, kidney transplantation, bioprinting and nephrotoxocity testing.Type: GrantFiled: May 24, 2018Date of Patent: November 8, 2022Assignees: MURDOCH CHILDRENS RESEARCH INSTITUTE, VANDERBILT UNIVERSITY, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OE VETERANS AFFAIRSInventors: Melissa Little, Jessica Vanslambrouck, Lauren Woodard, Matthew Wilson
-
Publication number: 20210177904Abstract: The invention relates to the treatment and prevention of problem behaviour by the administration of a composition that includes an effective amount of Prevotella.Type: ApplicationFiled: August 20, 2019Publication date: June 17, 2021Applicant: MURDOCH CHILDREN'S RESEARCH INSTITUTEInventors: Peter VUILLERMIN, Anne-Louise PONSONBY, Mimi TANG, Amy LOUGHMAN
-
Publication number: 20200399390Abstract: The invention relates to a method for producing a lymphocyte progenitor, the method comprising culturing a pluripotent stem cell (PSC)-derived CD34+ cell at an air-liquid interface (ALI). The invention also relates to a method for producing a B-cell progenitor, the method comprising co-culturing a PSC-derived CD34+ cell and a stromal cell in a medium comprising a CD117 activator and a NOTCH1 inhibitor. The invention further relates to a T-cell progenitor and a B-cell progenitor when produced by the methods of the invention and to use of the T-cell progenitor in the manufacture of T cell with defined antigen specificity, optionally a chimeric antigen receptor (CAR) T cell, and use of the B-cell progenitor in the manufacture of an antibody.Type: ApplicationFiled: March 8, 2018Publication date: December 24, 2020Applicant: MURDOCH CHILDRENS RESEARCH INSTITUTEInventors: Edouard Guy STANLEY, Andrew ELEFANTY, Ali MOTAZEDIAN
-
Patent number: 10745717Abstract: The invention relates to a vector comprising: a 5? nucleic acid that is homologous to a genomic sequence 5? of a stop codon of a constitutively expressed gene; an exogenous nucleic acid; a 3? nucleic acid that is homologous to a genomic sequence 3? of the stop codon of the constitutively expressed gene; a translation interruption-reinitiation signal operably linked to the 5? nucleic acid and the exogenous nucleic acid, wherein the translation interruption-reinitiation signal is capable of replacing the stop codon of the constitutively expressed gene.Type: GrantFiled: November 10, 2015Date of Patent: August 18, 2020Assignee: Murdoch Children's Research InstituteInventors: Ed Stanley, Andrew Elefanty, David Elliott, Tatiana Labonne
-
Patent number: 10301620Abstract: The present disclosure teaches the treatment of a blood pathology, such as a blood pathology associated with impaired hemoglobin synthesis including the treatment of ?-thalassemia or a related hemoglobinopathy. An RNA molecule such as a short interfering RNA or a hairpin RNA which targets an mRNA species encoding ?-globin is administered to a subject to reduce the amount of ?-globin produced to non-zero levels and ameliorate the effects of an ?- and ?-globin chain imbalance.Type: GrantFiled: December 20, 2011Date of Patent: May 28, 2019Assignee: MURDOCH CHILDRENS RESEARCH INSTITUTEInventor: Jim Vadolas
-
Patent number: 10138521Abstract: The present disclosure relates generally to the field of epigenetics and in particular epigenetic profiles associated with a pathological condition. The present specification teaches screening of individuals and populations for epigenetic profiles associated with a pathological condition. The epigenetic profiles can be from an intron, an intron/exon boundary or a splicing region. Epigenetic profiles are disclosed from the following sites in the FMR locus: FREE3, intron 2 of FMR1, the genomic FREE2 region as a whole or specific FREE2 fragments including FREE2 (D) or FREE2 (E). Kits and diagnostic assays are also taught herein as are computer programs to monitor changes in epigenetic patterns and profiles. Further enabled herein is a method for screening for agents which can reduce or mask the adverse effects of epigenetic modification and the use of these agents in therapy and prophylaxis.Type: GrantFiled: November 4, 2015Date of Patent: November 27, 2018Assignee: Murdoch Childrens Research InstituteInventor: David Eugeny Godler
-
Patent number: 10080892Abstract: A method of treating a waste evacuation dysfunction comprising administering transcutaneous electrical stimulation (TES) to at least one lower pelvic and/or sacral region for a specific treatment regimen. Also disclosed is a system for configuring a stimulation device to deliver transcutaneous electrical stimulation (TES) the system comprising: a computing device storing or having access to a plurality of TES settings and comprising a user interface to enable authorized selection of at least one of the TES settings for provision of TES by the stimulation device according to the at least one selected TES setting and the stimulation device communicatively coupled to the computing device to receive and store the selected at least one TES setting the stimulation device being of a size to be readily carried on a body and configured to selectively provide current to external electrode according to the one TES setting.Type: GrantFiled: June 27, 2017Date of Patent: September 25, 2018Assignee: Murdoch Childrens Research InstituteInventors: Bridget Rae Southwell, John Medwyn Hutson, Andre Yi Feng Tan
-
Patent number: 10071157Abstract: The present invention relates generally to the field of allergies. More particularly, the present invention provides a method for treating an allergy in a subject by inducing tolerance to an allergen associated with the allergy. Medicinal kits useful in protocols to induce tolerance or reduce intolerance in a subject also form part of the present invention.Type: GrantFiled: April 14, 2016Date of Patent: September 11, 2018Assignee: MURDOCH CHILDRENS RESEARCH INSTITUTEInventor: Mimi Lai-Kuan Tang
-
Patent number: 9969985Abstract: The present disclosure relates generally to the field of viral vaccines. Particularly, the present disclosure provides a modified Vero-adapted human rotavirus strain and a culturing method to produce high titer virus, a rotavirus vaccine, vaccination protocols and diagnostic and prognostic assays.Type: GrantFiled: August 26, 2013Date of Patent: May 15, 2018Assignee: Murdoch Childrens Research InstituteInventors: Carl Kirkwood, Ruth Frances Bishop, Graeme Laurence Barnes
-
Patent number: 9861816Abstract: Some embodiments relate to a method of treating a waste evacuation dysfunction, comprising administering transcutaneous electrical stimulation to at least one lumbar or abdominal region for at least one treatment period per day over a treatment term of at least one week.Type: GrantFiled: April 23, 2010Date of Patent: January 9, 2018Assignee: Murdoch Childrens Research InstituteInventors: Bridget Rae Southwell, John Medwyn Hutson, Andre Yi Feng Tan
-
Patent number: 9789308Abstract: A method of treating a waste evacuation dysfunction comprising administering transcutaneous electrical stimulation (TES) to at least one lower pelvic and/or sacral region for a specific treatment regimens. Also disclosed is a system for configuring a stimulation device to deliver transcutaneous electrical stimulation (TES) the system comprising: a computing device storing or having access to a plurality or TES settings and comprising a user interface to enable authorized selection of at least on of the TES settings for provision of TES by the stimulation device according to the at least one selected TES setting and the stimulation device communicatively coupled to the computing device to receive and store the selected at least one TES setting the stimulation device being of a size to be readily carried on a body and configured to selectively provide current to external electrode according to the one TES setting.Type: GrantFiled: March 2, 2012Date of Patent: October 17, 2017Assignee: MURDOCH CHILDRENS RESEARCH INSTITUTEInventors: Bridget Rae Southwell, John Medwyn Hutson, Andre Yi Feng Tan
-
Patent number: 9402896Abstract: The present invention relates generally to the field of allergies. More particularly, the present invention provides a method for treating an allergy in a subject by inducing tolerance to an allergen associated with the allergy. Medicinal kits useful in protocols to induce tolerance or reduce intolerance in a subject also form part of the present invention.Type: GrantFiled: January 30, 2009Date of Patent: August 2, 2016Assignee: MURDOCH CHILDRENS RESEARCH INSTITUTEInventor: Mimi Lai-Kuan Tang
-
Publication number: 20140212873Abstract: The present disclosure relates generally to the field of epigenetics and in particular epigenetic profiles associated with a pathological condition. The present specification teaches screening of individuals and populations for epigenetic profiles associated with a pathological condition. Epigenetic profiles are disclosed from the following sites in the FMR1 gene: FREE3, intron 2, an intron, intron/exon boundary and/or splicing region downstream of intron 2, and a site within the FREE2 portion of intron 1 in combination with a FM. Epigenetic profiles are also disclosed from a region in the FMR genetic locus selected from an intron, intron/exon boundary, a splicing region or an intragenic region in combination with an expansion mutation. Kits and diagnostic assays are also taught herein as are computer programs to monitor changes in epigenetic patterns and profiles.Type: ApplicationFiled: June 22, 2012Publication date: July 31, 2014Applicants: LA TROBE UNIVERSITY, MURDOCH CHILDRENS RESEARCH INSTITUTEInventor: David Eugeny Godler
-
Publication number: 20130338032Abstract: The present invention relates generally to an assay for the determination of epigenetic profiles, particularly epigenetic profiles associated with a pathological condition. Even more particularly, the present invention provides an assay to detect epigenetic profiles within the Fragile X Mental Retardation (FMR) genetic locus indicative of a pathoneurological condition such as pathoneurodevelopmental and pathoneurodegenerative conditions. The epigenetic profiles can also identify potential non-neurological conditions. Kits and assays for medicaments also form part of the present invention as do computer programs to monitor changes in epigenetic patterns and methods for screening for agents which modulate epigenetic modification.Type: ApplicationFiled: August 23, 2013Publication date: December 19, 2013Applicant: Murdoch Childrens Research InstituteInventor: DAVID EUGENY GODLER
-
Publication number: 20130218196Abstract: A therapeutic ischemic and reperfusion device with an associated monitoring system for generally enhancing the vascular and metabolic environment and wellbeing of a subject. A method for the treatment and prophylaxis of various medical conditions including environmental induced oxidative stress using the therapeutic ischemic and reperfusion device and associated monitoring system is also contemplated herein. The method uses an inflatable cuff around the limb or torso of a subject operated by a controller configured to inflate and deflate the cuff. The monitoring system is used to monitor the physical and metabolic environments of the subject during and subsequent to the ischemia and reperfusion.Type: ApplicationFiled: August 2, 2011Publication date: August 22, 2013Applicant: MURDOCH CHILDRENS RESEARCH INSTITUTEInventor: Michael Cheung
-
Publication number: 20130210007Abstract: The present disclosure relates generally to the field of epigenetics and in particular epigenetic profiles associated with a pathological condition. The present specification teaches screening of individuals and populations for epigenetic profiles associated with a pathological condition. The epigenetic profiles can be from an intron, an intron/exon boundary or a splicing region. Epigenetic profiles are disclosed from the following sites in the FMR locus: FREES, intron 2 of FMR1, the genomic FREE2 region as a whole or specific FREE2 fragments including FREE2 (D) or FREE2 (E). Kits and diagnostic assays are also taught herein as are computer programs to monitor changes in epigenetic patterns and profiles. Further enabled herein is a method for screening for agents which can reduce or mask the adverse effects of epigenetic modification and the use of these agents in therapy and prophylaxis.Type: ApplicationFiled: August 11, 2011Publication date: August 15, 2013Applicant: MURDOCH CHILDRENS RESEARCH INSTITUTEInventor: David Eugeny Godler
-
Patent number: D757952Type: GrantFiled: April 10, 2014Date of Patent: May 31, 2016Assignee: Murdoch Childrens Research InstituteInventors: Rod Wiebenga, Bridget Rae Southwell